Trial Profile
Phase II study of weekly topotecan with bevacizumab in platinum resistant recurrent ovarian, fallopian tube and primary peritoneal cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Topotecan (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 25 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2006 New trial record.